AbbVie Inc (ABBV)vsDermata Therapeutics Inc (DRMA)
ABBV
AbbVie Inc
$248.08
-0.73%
HEALTHCARE · Cap: $441.54B
DRMA
Dermata Therapeutics Inc
$1.34
0.00%
HEALTHCARE · Cap: $5.21M
Smart Verdict
WallStSmart Research — data-driven comparison
ABBV leads profitability with a 5.8% profit margin vs 0.0%. ABBV earns a higher WallStSmart Score of 63/100 (C+).
ABBV
Buy63
out of 100
Grade: C+
DRMA
Avoid26
out of 100
Grade: F
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
-69.2%
Fair Value
$146.57
Current Price
$248.08
$101.51 premium
Intrinsic value data unavailable for DRMA.
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Mega-cap, among the largest globally
Growing faster than its price suggests
Every $100 of equity generates 62 in profit
Strong operational efficiency at 32.2%
Conservative balance sheet, low leverage
Generating 3.6B in free cash flow
Reasonable price relative to book value
Areas to Watch
5.8% margin — thin
Premium valuation, high expectations priced in
Earnings declined 46.2%
Distress zone — elevated risk
0.0% revenue growth
0.0% earnings growth
Smaller company, higher risk/reward
0.0% margin — thin
Comparative Analysis Report
WallStSmart ResearchBull Case : ABBV
The strongest argument for ABBV centers on Market Cap, PEG Ratio, Return on Equity. Revenue growth of 12.4% demonstrates continued momentum. PEG of 0.41 suggests the stock is reasonably priced for its growth.
Bull Case : DRMA
The strongest argument for DRMA centers on Price/Book.
Bear Case : ABBV
The primary concerns for ABBV are Profit Margin, P/E Ratio, EPS Growth. A P/E of 123.7x leaves little room for execution misses.
Bear Case : DRMA
The primary concerns for DRMA are Revenue Growth, EPS Growth, Market Cap.
Key Dynamics to Monitor
DRMA carries more volatility with a beta of 0.69 — expect wider price swings.
ABBV is growing revenue faster at 12.4% — sustainability is the question.
ABBV generates stronger free cash flow (3.6B), providing more financial flexibility.
Monitor DRUG MANUFACTURERS - GENERAL industry trends, competitive dynamics, and regulatory changes.
Bottom Line
ABBV scores higher overall (63/100 vs 26/100) and 12.4% revenue growth. Both earn "Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
AbbVie Inc
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
AbbVie is an American publicly traded biopharmaceutical company founded in 2013. It originated as a spin-off of Abbott Laboratories.
Dermata Therapeutics Inc
HEALTHCARE · BIOTECHNOLOGY · USA
Dermata Therapeutics Inc. is a clinical-stage biotechnology company dedicated to innovating treatments for dermatological conditions, with a primary focus on its lead candidate, DMT310. Employing a proprietary delivery system, DMT310 aims to enhance the effectiveness of acne therapies and address critical unmet needs in the dermatology sector. With a strategically developed pipeline and a commitment to pioneering solutions, Dermata is poised to significantly impact the skin health landscape and improve patient outcomes. As the company progresses through its clinical trials, it holds the potential to become a transformative force in the treatment of various skin disorders.
Compare with Other DRUG MANUFACTURERS - GENERAL Stocks
Want to dig deeper into these stocks?